It has been suggested that long term treatment with calneither drug produced a detectable effect on ex vivo platelet aggregation, platelet retention, or thromboxane cium antagonist drugs might inhibit platelet function and lead to an anti-atheromatous effect. However recent generation with adrenaline, collagen, adenosinedi-phosphate, or platelet activating factor. However a data have also suggested that such an effect might increase mortality due to an increased incidence of gasdecrease in plasma ␤-thromboglobulin levels was observed which reached statistical significance (P Ͻ trointestinal bleeding.
Introduction
been demonstrated to inhibit platelet aggregation in While calcium antagonists are frequently used in the vitro, 6-8 the doses required have been very high and treatment of hypertension and coronary heart diswould be difficult to achieve in the clinical situease, several recent studies have questioned their ation. Results of in vivo studies have been difficult long term safety. Apart from a meta-analysis and a to interpret because of unsatisfactory experimental case control study which suggested a greater morcontrols.
5,9
tality rate with calcium antagonists 1,2 and evidence Our study was designed to examine the comparaof a possible greater risk of cancer, 3 analysis of the tive effects of the dihydropyridine isradipine and same database of elderly patients has suggested an the ␤-blocker atenolol on ex vivo platelet function increased risk of gastrointestinal haemorrhage for in hypertensive patients whose blood pressure (BP) hypertensive patients on calcium antagonists when had been reduced by either drug as monotherapy. compared to ␤-blockers. 4 The potential for calcium The design was a randomised, parallel group, douantagonists, particularly dihydropyridines, to ble-blind comparison over 12 weeks of active treatinhibit platelet function and promote vasodilation ment with a preliminary 4-week placebo 'run-in' were the suggested mechanisms. However, evidence and 4-week placebo 'washout' period. The ␤-blocker that calcium channel blockers in general, and dihydatenolol was used since it does not appear to alter ropyridines in particular, can significantly inhibit platelet function. Moreover, recent studies on haemplatelet function in vivo in the hypertensive popuorrhagic, vascular and cancer mortality rates relied on comparisons between calcium antagonists and
Patients and methods
0.19 mM) from Boehringer Mannheim (Mannheim, Patients aged between 40 and 60 years with mild to Germany). The velocity slopes of primary and secmoderate hypertension (diastolic BP 95-109 ondary aggregation (mm/min) were measured; for mm Hg) were recruited from general practice.
collagen the lag phase (seconds) was also measured. Patients were excluded if they were taking any Thromboxane B 2 (TXB 2 ) was measured by radioimmedications known to influence lipids, platelet munossay. TXB 2 standard and TXB 2 antiserum were function, or BP; had DBPs у110 mm Hg and/or sysobtained from Sigma Chemical Co and tritiated tolic pressures у180 mm Hg at any phase of the TXB 2 from New England Nuclear (Du Pont NEN, study; had a history of vascular disease (angina, Boston, MA, USA). TXB 2 generation was measured myocardial infarction, transient ischaemic attack, in response to adrenaline (5.5 mM), ADP (1.25 M), stroke, claudication or any current disturbance in collagen (0.5 g/mL) and PAF (0.19 mM). Aggrecardiac rhythm); had a history of diabetes mellitus, gation was allowed to proceed for 6 min after which asthma or history of drug or alcohol abuse. Female an equal volume of 70% ice cold ethanol was added patients in the reproductive age group were also to the cuvette. The sample was immediately mixed excluded. A research nurse visited patients identand transferred to polypropylene tubes on ice until ified by participating doctors who confirmed their centrifugation at 2000 g for 30 min at 4°C. The suitability for inclusion and obtained informed consupernatants were stored at −80°C until assay. The sent. The patient then entered a 4-week run-in plainterassay variability was 12%; range of assay 350-cebo period. At randomisation, fasting venous blood 560 pg/mL; results expressed as mg/10 8 platelets. was collected for platelet function studies, plasma Plasma ␤-thromboglobulin assay was performed ␤-thromboglobulin and euglobulin lysis time, lipids, using the Amersham kit (Amersham, UK) and blood electrolytes, renal, and hepatic function. Supine (10 samples were collected into the tubes provided. Plamin) and erect (5 min) BP was measured prior to telet retention was measured using heparinised the blood test with a mercury sphygmomanometer.
whole blood collected in 10 mL syringes without Patients were then allocated to either isradipine or disturbance; retention was measured progressively atenolol. Starting doses were 1.25 mg BD isradipine in the first 5 mL emerging from a glass bead color 50 mg atenolol (plus one placebo tablet to mainumn. 10 Haemoglobin, total and differential white tain the blind), and all patients agreed to take their cell count, platelet count and red cell indices were medications between 06.00 and 08.00 hours. measured on a Coulter S Plus Jr; blood films were Patients were reviewed at 2 and then 4 weeks. If the reviewed if indicated. Biochemical analyses were DBP was Ͼ95 mm Hg, the drug dose was doubled.
performed on a Technicon SMAC-2 (Bayer DiagnosAt weeks 4 and 12, all blood studies were repeated.
tics, Australia). Serum total cholesterol, high density Following completion of 12 weeks of active treatlipoprotein and triglycerides were performed using ment, all patients entered a final 4-week placebo a Roche Cobas-Bio (Roche Diagnostics, Basel, (washout) phase and the blood tests were repeated. Switzerland). All blood samples were collected in the laboratory at approximately the same time (am). This study was approved by the Hunter Area Research Ethics Com-
Results

mittee.
Of 43 patients identified, 24 patients (15 male, 9 female) were eligible for study entry. There were no Laboratory methods significant differences in BP, age, weight or height All blood samples were collected from an antecubibetween the two groups at entry (Table 1) . Two tal vein without stasis through a 19 gauge needle.
patients failed to complete the 12-week active treatBlood for platelet aggregation, platelet retention, ment period; one withdrew from the isradipine thromboxane generation, and euglobulin lysis time, group at week 3 because of headaches and lethargy was collected into tubes containing 0.1 volume of and one withdrew from the atenolol group at week 3.13% tri-sodium citrate dihydrate. Platelet-rich 8 due to lethargy and impotence. All other patients plasma (PRP) and platelet-poor plasma (PPP) were completed the study without significant adverse prepared by centrifugation at 22°C at 120 g for 10 events. min and 3000 g for 20 min, respectively. The PRP was divided into 4 -5 mL aliquots and stored under 5% CO 2 in oxygen in sealed tubes at 22°C until tested. Platelet aggregation was performed at 37°C BP responses using a dual channel Chronolog aggregometer (Chronolog Corporation, Havertown, PA, USA) and Three patients achieved satisfactory BP control with 2.5 mg of isradipine daily while eight required 5 mg was completed within 4 h of blood collection. PRP was not corrected to a standard platelet count. Agondaily. Five atenolol patients achieved control with 50 mg while six required 100 mg daily. BP falls with ists tested were: adenosine-5′-diphosphate (ADP, final concentration 1.25 and 2.5 M) from Sigma drug treatment were similar in each treatment group (supine and erect) and returned towards pretreatChemical Co (St Louis, MO, USA); collagen reagent Horm (0.5 and 1.0 g/mL) from Paton Scientific ment levels during the washout period. The pulse rate was significantly reduced with atenolol ( Isradipine: Age 53 ± 3 years; weight 87 ± 5 kg; height 170 ± 3 cm Systolic mm Hg 167 ± 2 153 ± 3* 153 ± 3* 160 ± 2 Diastolic mm Hg 102 ± 1 9 2 ± 2* 91 ± 2* 101 ± 2 Pulse bpm 85 ± 4 8 7 ± 2 8 2 ± 3 8 2 ± 2 Atenolol: Age 56 ± 4 years; weight 85 ± 5 kg; height 171 ± 3 cm Systolic mm Hg 165 ± 2 153 ± 4* 156 ± 4* 167 ± 4 Diastolic mm Hg 101 ± 1 8 6 ± 2* 91 ± 2* 100 ± 2 Pulse bpm 78 ± 4 7 1 ± 5* 70 ± 3* 83 ± 3 *Significantly different from control (and placebo) P Ͻ 0.05 (paired t-test).
Platelet function
There were no significant differences during the study period or between the two treatment groups in the slopes of primary aggregation with ADP or adrenaline or the slopes of aggregation with PAF or collagen. The lag time for collagen-induced aggregation was similar in both treatment groups and did not alter over the treatment period. Similarly, no significant differences in agonist-induced thromboxane generation were observed over the study period or between treatment groups. Platelet retention did not alter significantly in either group throughout the study. Platelet numbers were also similar in both groups and did not change over the study period.
Plasma ␤-thromboglobulin (Table 2 , Figure 1) In the isradipine patients, mean pre-randomised levels were almost identical to those measured at the end of washout. Values measured at 4 and 12 weeks of active treatment were lower and this difference was statistically significant at 12 weeks. A similar but nonsignificant trend was observed in the atenolol group where, although baseline levels were somewhat higher (although still within the reference interval), they also tended to fall over the active treatment period. The mean reduction was 35% compared to a 39% reduction during isradipine treatment.
Euglobulin clot lysis time
Results were consistently within the reference inter- cholesterol. The total to HDL cholesterol ratio was 4.5 and 4.4 before and after isradipine treatment seen in patients treated with atenolol, although the levels did not return to baseline after the 4-week respectively and 5.3 and 5.9 with atenolol. A small nonsignificant increase in triglycerides was noted washout period. As other laboratories have also observed a reduction in baseline ␤-thromboglobulin with atenolol. levels in hypertensive patients receiving isradipine, 5,14-16 as well as in patients receiving atenolol,
16
Discussion this could be interpreted as representing a reduction in the level of in vivo platelet activation. However, The aim of the study was to achieve an acceptable and similar control of BP in both the isradipine and in a study where plasma ␤-thromboglombulin was measured as a marker of in vivo platelet activation, 18 atenolol groups, so that any differences found between the groups in platelet function, fibrinolytic untreated hypertensive patients had significantly higher levels than normotensive controls. Angiotenactivity or lipid profile could not be attributed to differences in the level of BP control which was achsion-converting enzyme (ACE) inhibitors appeared to be more effective than calcium channel blockers ieved. The strict entry criteria excluded a number of hypertensive patients who would have been in reducing plasma levels in this study. It is therefore likely that the ␤-thromboglobulin changes noted included in a simple comparative study of efficacy. Although patients were rigorously selected, and in our study and others reflect the fall in BP rather than a direct drug effect. That these effects of isradiclearly instructed to avoid aspirin, platelet function tests had to be repeated on 10 occasions (11% of pine, other calcium channel blockers, and other antihypertensive drugs are related to BP reduction visits) because patients had inadvertently taken aspirin containing compounds, usually as over-theis supported by evidence that hypertension and hypercholesterolaemia increase the sensitivity of counter medications in which the presence of aspirin was not clearly shown.
platelets to activating agents. 19 Also, platelet aggregation during treatment with diverse calcium chanIn the two groups of patients matched for initial BP elevation, BP was reduced to a similar and satisnel blockers (nisoldipine, nifedipine, diltiazem, and verapamil) was related to their BP lowering ability factory extent in both groups. A mean dose of 4.3 mg isradipine in divided doses proved to have an and platelet function was normalised, not depressed.
20 equivalent effect to a mean dose of 81.8 mg/day atenolol and there were no serious adverse effects.
In vivo studies have evaluated the effects of other calcium channel blockers on platelet function. HowNo significant haematological or biochemical abnormality was noted during the course of the study and ever, again, the changes reported are inconsistent and trial designs often suboptimal. A comparison of plasma lipid parameters were not significantly altered in either group. nifedipine with cilazapril 21 and propranolol and verapamil 22 failed to demonstrate any effect on platBlood was collected and platelet studies performed under strictly controlled conditions and there elet function or blood rheology although both propranolol and verapamil reduced plasma ␤-thromwas no evidence of a significant drug effect on aggregation or thromboxane generation with a range of boglobulin levels. However the same laboratory found that felodipine treatment for 12 weeks agonists. Previous reports of a platelet effect of isradipine were based on in vitro addition of relatively reduced ADP-induced platelet aggregation. 23 In contrast Wilson et al 24 could not demonstrate any effect high drug concentrations to the PRP, 6,7,11 rather than ex vivo studies of drug treated patients. Ding et al 9 of nifedipine or felodipine on platelet responsiveness to collagen or ADP, despite a fall in platelet reported inhibition of adrenaline-induced aggregation after 12 weeks of isradipine therapy (2.5-5 basal cytoplasmic calcium. Zucker et al 25 have reported that treatment with the non-dihydropyridmg daily) but did not include a control group. Fetkovska et al 12, 13 reported that isradipine reduces plaine diltiazem for 1 week reduced platelet aggregation and nucleotide release induced by sub-threstelet aggregation induced by serotonin in combination with low density lipoprotein (LDL), and hold concentrations of paired agonists (arachidonate and adrenaline) in normal volunteers. However the while they used a 4-week run-in placebo period, the study group was not controlled. Three other studies in vitro ability of ditiazem to potentiate the inhibitory effect of aspirin on platelet aggregation 8 with that reported a reduction in ADP or serotonininduced platelet aggregation 5,14,15 also did not this drug could not be demonstrated in vivo. Amlodipine and quinalapril did not appear to alter plateinclude a control group, nor was there evidence that concomitant and unintentional aspirin use was avolet function. 26 Dihydopyridines bind to the ␣ 1 -subunit of the Lided. Gleerup et al 16 found that both isradipine and atenolol decreased platelet activity following thertype voltage-activated calcium channel and in this way exert their influence on calcium-mediated apy. Fitscha et al 5 also reported a reduction in serum TXB 2 levels, however, they did not examine agonistevents such as smooth muscle contraction and cardiac excitation. Recently, putative dihydropyridineinduced thromboxane generation. Interestingly, Klauser et al 17 in a small, blinded, cross-over consensitive channels were described in platelets 27 giving a credible target for platelet interaction with caltrolled study, reported that isradipine had no effect on collagen or ADP-induced platelet aggregation. cium channel blocking drugs. Many actions and interactions of platelets are calcium-dependant. While changes in baseline plasma ␤-thromboglobulin, a marker of platelet ␣-granule release, appeared This is not to say that they are calcium-channeldependant but rather that they depend on local conconsistent and drug-related with isradipine in our study, a lesser fall over the study period was also centrations of calcium either around or within the plasma concentrations of isradipine which are likely
